women ≥ 80 cm; (3) TG levels ≥ 1.70 mmol/L or under lipid-lowering therapy; (4) HDL-C levels < 1.0 mmol/L for men and < 1.3 mmol/L for women or on lipid-lowering therapy; (5) Pre-diabetes, FPG of 5.6 ~ 6.9 mmol/L or HbA1c of 5.7 ~ 6.4%...
The impact of high-intensity rosuvastatin and a combination of low-intensity rosuvastatin and ezetimibe on HbA1c levels in patients without diabetes (IDEAL; KCT0007278) study was a single-center, prospective, open-label, randomized trial. This study compared the effects of the combination of low-...